Somerset facility State-of-the art facility for clinical and commercial manufacturing of oral dosage forms. Ghent, Belgium, ...

CTLT announces an agreement to sell its oral solids development and manufacturing facility in Somerset to Ardena.

Awaiting a potential acquisition by Novo Holdings, Catalent is giving its contract manufacturing compatriot a boost as Ardena ...

Catalent一直在其他地方扩大其口服固体剂量能力，在美国和欧洲进行了大量投资。值得注意的是，2022年10月，Catalent以4.75亿美元收购了北卡罗来纳州格林维尔一座333,000平方英尺的设施，从而加强了其地位。该设施具备处理高效活性药物成分 (API)的先进能力，并为口服固体剂型提供全面服务。

合同制造服务提供商Catalent已达成协议，将其位于新泽西州萨默塞特的口服药物开发和小规模制造工厂出售给私人合同药品制造商Ardena。该交易于今日宣布。 这座获得美国食品和药物管理局(FDA)批准的萨默塞特工厂拥有约200名科学家和技术人员。Ardena表示，收购这座工厂将增强其在口服药物商业化生产方面的能力。 Catalent以其灌装完成工作而闻名，包括为制药公司进行注射器和注射笔的无菌灌装 ...

Catalent entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in ...

At CPHI Milan 2024, Ardena will showcase its latest advancements in drug development and manufacturing, including the launch ...

Catalent has agreed to sell its oral drug development and small-scale manufacturing facility in Somerset, New Jersey to ...

Catalent (NYSE:CTLT) is selling its oral solids development and small-scale manufacturing facility in Somerset, New Jersey to ...

Catalent, Inc. (CTLT), a provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer ...

The site also serves as an oral solids development and small-scale manufacturing facility for the pharmaceutical company, ...

Catalent has agreed to sell its oral drug development and small-scale manufacturing facility in Somerset, New Jersey to private contract drug manufacturer Ardena, the companies said on Monday.